Recovery
Aviptadil
Also called VIP, RLF-100
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the EU, only as a fixed combination with phentolamine.
The human evidence for Aviptadil used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 0.33mg/mL
- Volume per draw
- 0.08mL
- Units to dial
- 8
- Doses per cartridge
- 37
Requested 0.075 mL
Requested 7.5
7.5 units is between clicks. The nearest setting is 8, which delivers 26.7 mcg instead of 25 mcg.
Vial label
Copy this into your label printer.
Published research contexts for Aviptadil describe 25–100 mcg per administration. Descriptive only, not a recommendation.
Minutes-scale in plasma; VIP is degraded rapidly, so the decay chart is largely illustrative here.
A vasoactive intestinal peptide (VIP). The human evidence is intravenous, with additional inhaled studies, and it is licensed in the EU only as a fixed combination with phentolamine, given by injection. No subcutaneous dose-ranging schedule is established, so no schedule table is shown and the vial size shown is nominal.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.90× single dose
- Time to steady state
- 0hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Aviptadil/phentolamine combination-injection literatureAviptadil (VIP) is licensed in the EU only as a fixed combination with phentolamine, given by injection.
- RLF-100 (aviptadil) intravenous and inhaled studiesHuman studies used intravenous infusion and inhalation; no subcutaneous schedule was fixed.